{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T10:28:07Z","timestamp":1786703287439,"version":"build-2736575974"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To characterize early changes in skeletal muscle and physical function among patients with advanced non-small cell lung cancer (NSCLC) receiving penpulimab monotherapy or combination therapy, and to identify distinct treatment-associated physiological phenotypes with potential clinical relevance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We retrospectively analyzed 381 patients with advanced NSCLC (monotherapy,\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a0153; combination therapy,\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a0228) treated between September 2021 and March 2023. Inverse probability of treatment weighting (IPTW) was applied to balance baseline characteristics between treatment groups. Skeletal muscle index (SMI), muscle attenuation, and functional measures were assessed at baseline and 12 weeks. Unsupervised clustering was performed to identify early physiological phenotypes based on longitudinal changes in muscle and functional parameters. Exploratory survival analyses were conducted using 12-week landmark models to evaluate the association between physiological phenotypes and overall survival (OS).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>After IPTW adjustment, combination therapy was associated with greater early physiological deterioration, including larger declines in muscle mass and physical performance, increased incidence of new-onset sarcopenia, and poorer treatment tolerability compared with monotherapy. Unsupervised clustering identified three distinct physiological phenotypes: Stable (P1), Wasting (P2), and Collapse (P3). Combination therapy was associated with a higher likelihood of transition to vulnerable phenotypes, particularly P2 and P3. These phenotypes demonstrated distinct clinical characteristics and survival patterns, with the Collapse phenotype exhibiting the poorest OS (median OS, 18.0 months), whereas OS was not reached in the Stable phenotype. Incorporation of physiological phenotypes improved the discrimination of landmark survival models beyond baseline clinical characteristics and radiographic response assessments. Exploratory pathway analyses suggested potential associations between early physiological deterioration patterns and survival differences; however, these findings require prospective validation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Early treatment-associated physiological deterioration in advanced NSCLC is heterogeneous and can be characterized by reproducible dynamic phenotypes. Combination therapy is associated with greater early declines in muscle and physical function, while longitudinal physiological phenotyping provides complementary information for identifying patients at increased risk of adverse outcomes beyond conventional tumor response assessment. Prospective studies are warranted to validate these findings and determine whether interventions targeting physiological decline can improve clinical outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1882281","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T09:34:10Z","timestamp":1786700050000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Early physiological phenotypes and survival outcomes in advanced non-small cell lung cancer: a longitudinal study of dynamic muscle loss and functional decline"],"prefix":"10.3389","volume":"16","author":[{"given":"Liang","family":"Yan","sequence":"first","affiliation":[{"name":"Department of Radiotherapy and Chemotherapy, The Second Affiliated Hospital of Xingtai Medical College","place":["Xingtai, Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongcun","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy and Chemotherapy, The Second Affiliated Hospital of Xingtai Medical College","place":["Xingtai, Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy and Chemotherapy, The Second Affiliated Hospital of Xingtai Medical College","place":["Xingtai, Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuepin","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy and Chemotherapy, The Second Affiliated Hospital of Xingtai Medical College","place":["Xingtai, Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-025-01061-7","article-title":"Treatment of NSCLC after chemoimmunotherapy - are we making headway","volume":"22","author":"Reck","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00794-7","article-title":"Immune-checkpoint inhibition for resectable non-small-cell lung cancer - opportunities and challenges","volume":"20","author":"Mountzios","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"22","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(23)00431-9","article-title":"First-line penpulimab combined with paclitaxel and carboplatin for metastatic squamous non-small-cell lung cancer in China (AK105-302): a multicentre, randomised, double-blind, placebo-controlled phase 3 clinical trial","volume":"12","author":"Zhong","year":"2024","journal-title":"Lancet Respir Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-024-03442-3","article-title":"Comparison of efficacy and safety of PD-1\/PD-L1 combination therapy in first-line treatment of advanced NSCLC: an updated systematic review and network meta-analysis","volume":"26","author":"Yang","year":"2024","journal-title":"Clin Transl Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1097\/JS9.0000000000002714","article-title":"Efficiency and safety of neoadjuvant PD-1 inhibitor (penpulimab) combined with chemotherapy in resectable N1\/N2 nonsmall cell lung cancer: a prospective cohort study","volume":"111","author":"Zhou","year":"2025","journal-title":"Int J Surg"},{"key":"B7","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ejca.2015.12.030","article-title":"Prognostic value of sarcopenia in adults with solid tumours: a meta-analysis and systematic review","volume":"57","author":"Shachar","year":"2016","journal-title":"Eur J Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1089\/ars.2022.0149","article-title":"Targeting mitochondria and oxidative stress in cancer- and chemotherapy-induced muscle wasting","volume":"38","author":"Huot","year":"2023","journal-title":"Antioxid Redox Signal"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-023-01675-y","article-title":"The immunometabolic ecosystem in cancer","volume":"24","author":"Bantug","year":"2023","journal-title":"Nat Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-022-08980-4","article-title":"Sarcopenia and myosteatosis are associated with survival in patients receiving immunotherapy for advanced hepatocellular carcinoma","volume":"33","author":"Chen","year":"2023","journal-title":"Eur Radiol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnesp.2021.01.009","article-title":"Myosteatosis is prognostic in metastatic melanoma treated with nivolumab","volume":"42","author":"Youn","year":"2021","journal-title":"Clin Nutr ESPEN"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16071395","article-title":"Clinical relevance of physical function outcomes in cancer cachexia","volume":"16","author":"Caeiro","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/jcsm.12785","article-title":"Inflammatory markers are associated with quality of life, physical activity, and gait speed but not sarcopenia in aged men (40-79 years)","volume":"12","author":"Dupont","year":"2021","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"B14","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.chest.2016.10.010","article-title":"The eighth edition lung cancer stage classification","volume":"151","author":"Detterbeck","year":"2017","journal-title":"Chest"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2021.05.011","article-title":"Body composition and dose-limiting toxicity in colorectal cancer chemotherapy treatment; a systematic review of the literature. Could muscle mass be the new body surface area in chemotherapy dosing","volume":"33","author":"Drami","year":"2021","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114024","article-title":"Paclitaxel therapeutic drug monitoring - International association of therapeutic drug monitoring and clinical toxicology recommendations","volume":"202","author":"Hertz","year":"2024","journal-title":"Eur J Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.5848","article-title":"Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial","volume":"30","author":"Socinski","year":"2012","journal-title":"J Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1139\/H08-075","article-title":"A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care","volume":"33","author":"Mourtzakis","year":"2008","journal-title":"Appl Physiol Nutr Metab"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(08)70153-0","article-title":"Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study","volume":"9","author":"Prado","year":"2008","journal-title":"Lancet Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.45.2722","article-title":"Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index","volume":"31","author":"Martin","year":"2013","journal-title":"J Clin Oncol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.jamda.2019.12.012","article-title":"Asian Working Group for Sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment","volume":"21","author":"Chen","year":"2020","journal-title":"J Am Med Dir Assoc"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000003164","article-title":"Sarcopenia is an independent predictor of severe postoperative complications and long-term survival after radical gastrectomy for gastric cancer: analysis from a large-scale cohort","volume":"95","author":"Zhuang","year":"2016","journal-title":"Med (Baltimore)"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.5791","article-title":"Derivation, validation, and potential treatment implications of novel clinical phenotypes for sepsis","volume":"321","author":"Seymour","year":"2019","journal-title":"JAMA"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.csda.2006.11.025","article-title":"Cluster-wise assessment of cluster stability","volume":"52","author":"Hennig","year":"2007","journal-title":"Comput Stat Data Anal"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2009.00671.x","article-title":"Use of stabilized inverse propensity scores as weights to directly estimate relative risk and its confidence intervals","volume":"13","author":"Xu","year":"2010","journal-title":"Value Health"},{"key":"B28","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"201","journal-title":"Multivariate Behav Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/sim.6607","article-title":"Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies","volume":"34","author":"Austin","year":"2015","journal-title":"Stat Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwy201","article-title":"Addressing extreme propensity scores via the overlap weights","volume":"188","author":"Li","year":"2019","journal-title":"Am J Epidemiol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.tem.2021.03.007","article-title":"Cancer-mediated muscle cachexia: etiology and clinical management","volume":"32","author":"Siff","year":"2021","journal-title":"Trends Endocrinol Metab"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00541-y","article-title":"Metabolic barriers to cancer immunotherapy","volume":"21","author":"DePeaux","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.nut.2022.111829","article-title":"Contribution of skeletal muscle to cancer immunotherapy: a focus on muscle function, inflammation, and microbiota","volume":"105","author":"Deng","year":"2023","journal-title":"Nutrition"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s12603-019-1273-z","article-title":"Physical frailty: ICFSR international clinical practice guidelines for identification and management","volume":"23","author":"Dent","year":"2019","journal-title":"J Nutr Health Aging"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-023-02200-6","article-title":"Cancer cachexia and chronic inflammation: an unbreakable bond","volume":"128","author":"Macci\u00f2","year":"2023","journal-title":"Br J Cancer"},{"key":"B36","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1002\/jpen.2607","article-title":"Creatine supplementation for optimization of physical function in the patient at risk of functional disability: a systematic review and meta-analysis","volume":"48","author":"Davies","year":"2024","journal-title":"JPEN J Parenter Enteral Nutr"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/s43587-021-00136-1","article-title":"Toward the recognition and management of sarcopenia in routine clinical care","volume":"1","author":"Dent","year":"2021","journal-title":"Nat Aging"},{"key":"B38","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1001\/jamasurg.2024.4800","article-title":"Diagnosis of respiratory sarcopenia for stratifying postoperative risk in non-small cell lung cancer","volume":"160","author":"Sun","year":"2025","journal-title":"JAMA Surg"},{"key":"B39","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1097\/COC.0000000000001152","article-title":"Prognostic impact of low muscle mass and inflammatory markers in stage III nonsmall cell lung cancer Turkish Oncology Group and Turkish Society of Radiation Oncology Thoracic Cancer Study Group (08-005)","volume":"48","author":"Gumustepe","year":"2025","journal-title":"Am J Clin Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1882281\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T09:34:11Z","timestamp":1786700051000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1882281\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,14]]},"references-count":39,"alternative-id":["10.3389\/fonc.2026.1882281"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1882281","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,14]]},"article-number":"1882281"}}